WO2010059773A1 - Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators - Google Patents
Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators Download PDFInfo
- Publication number
- WO2010059773A1 WO2010059773A1 PCT/US2009/065060 US2009065060W WO2010059773A1 WO 2010059773 A1 WO2010059773 A1 WO 2010059773A1 US 2009065060 W US2009065060 W US 2009065060W WO 2010059773 A1 WO2010059773 A1 WO 2010059773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- methyl
- quinazolin
- pharmaceutically acceptable
- Prior art date
Links
- 0 CC(C=CC(Cc(cc12)c(cccc3)c3c1N=CN([C@@](CCCC1)[C@@]1O)C2=O)=*)=[N+] Chemical compound CC(C=CC(Cc(cc12)c(cccc3)c3c1N=CN([C@@](CCCC1)[C@@]1O)C2=O)=*)=[N+] 0.000 description 3
- OFPWMRMIFDHXFE-UHFFFAOYSA-N BrCc1ccccn1 Chemical compound BrCc1ccccn1 OFPWMRMIFDHXFE-UHFFFAOYSA-N 0.000 description 1
- UMOHCRAMELOQTA-CGMIVPLMSA-N C/C=C\C=C(/C(C(Cc1ccc(C)nc1)=C1)=C)\C(N=CN2[C@@H](CCCC3)[C@H]3O)=C1C2=O Chemical compound C/C=C\C=C(/C(C(Cc1ccc(C)nc1)=C1)=C)\C(N=CN2[C@@H](CCCC3)[C@H]3O)=C1C2=O UMOHCRAMELOQTA-CGMIVPLMSA-N 0.000 description 1
- XBCBQCBHDRDOAL-VROPFNGYSA-N CC1(C)OB(c(cc23)c(cc(C)cc4)c4c2N=CN([C@@H](CCCC2)[C@H]2O)C3=[U])OC1(C)C Chemical compound CC1(C)OB(c(cc23)c(cc(C)cc4)c4c2N=CN([C@@H](CCCC2)[C@H]2O)C3=[U])OC1(C)C XBCBQCBHDRDOAL-VROPFNGYSA-N 0.000 description 1
- DYZOHRHLSXXOHM-VXKWHMMOSA-N CS(c1ncc(Cc(c2c3cccc2)cc2c3N=CN([C@@H](CCCC3)[C@H]3O)C2=O)cc1)(=O)=O Chemical compound CS(c1ncc(Cc(c2c3cccc2)cc2c3N=CN([C@@H](CCCC3)[C@H]3O)C2=O)cc1)(=O)=O DYZOHRHLSXXOHM-VXKWHMMOSA-N 0.000 description 1
- HRDRILXRILWROH-IMMUGOHXSA-N CSc1ccc(Cc(cc23)c(cccc4)c4c2N=CN(CC(CCCC2)[C@H]2O)C3=O)cn1 Chemical compound CSc1ccc(Cc(cc23)c(cccc4)c4c2N=CN(CC(CCCC2)[C@H]2O)C3=O)cn1 HRDRILXRILWROH-IMMUGOHXSA-N 0.000 description 1
- JUVQLZBJFOGEEO-NQCNTLBGSA-O Cc1[nH+]cc(Cc(cc23)c(cccc4)c4c2N=CN([C@@H](CCCC2)C2O)C3=O)cc1 Chemical compound Cc1[nH+]cc(Cc(cc23)c(cccc4)c4c2N=CN([C@@H](CCCC2)C2O)C3=O)cc1 JUVQLZBJFOGEEO-NQCNTLBGSA-O 0.000 description 1
- QJPKSLLXINNKIN-UHFFFAOYSA-O O=C(CCCC1)C1[NH+](C=Nc1c(cccc2)c2c(Cc(cn2)ccc2Cl)cc11)C1=O Chemical compound O=C(CCCC1)C1[NH+](C=Nc1c(cccc2)c2c(Cc(cn2)ccc2Cl)cc11)C1=O QJPKSLLXINNKIN-UHFFFAOYSA-O 0.000 description 1
- ULOGSUJEHYGYBR-UHFFFAOYSA-N O=C(c1c2)N(C3CCCCC3)C=Nc1c(cccc1)c1c2Br Chemical compound O=C(c1c2)N(C3CCCCC3)C=Nc1c(cccc1)c1c2Br ULOGSUJEHYGYBR-UHFFFAOYSA-N 0.000 description 1
- ABNCFPYCMDGBQM-SFTDATJTSA-N O[C@@H](CCCC1)[C@H]1N(C=Nc1c(cccc2)c2c(Cc(cc2)cnc2Cl)cc11)C1=O Chemical compound O[C@@H](CCCC1)[C@H]1N(C=Nc1c(cccc2)c2c(Cc(cc2)cnc2Cl)cc11)C1=O ABNCFPYCMDGBQM-SFTDATJTSA-N 0.000 description 1
- DJUWOLPWLMUYOT-VXKWHMMOSA-N O[C@@H](CCCC1)[C@H]1N(C=Nc1c(cccc2)c2c(Cc2ccccn2)cc11)C1=O Chemical compound O[C@@H](CCCC1)[C@H]1N(C=Nc1c(cccc2)c2c(Cc2ccccn2)cc11)C1=O DJUWOLPWLMUYOT-VXKWHMMOSA-N 0.000 description 1
- VIPAKOFFKWURAL-HXOBKFHXSA-N O[C@@H]1[C@@H](CN(C=Nc2c(cccc3)c3c(Cc3ccccn3)cc22)C2=O)CCCC1 Chemical compound O[C@@H]1[C@@H](CN(C=Nc2c(cccc3)c3c(Cc3ccccn3)cc22)C2=O)CCCC1 VIPAKOFFKWURAL-HXOBKFHXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
- C07C53/21—Acids containing three or more carbon atoms containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011537601A JP5102397B2 (ja) | 2008-11-20 | 2009-11-19 | アリールメチルベンゾキナゾリノンｍ１レセプターポジティブアロステリックモジュレーター |
| DK09761104.0T DK2358686T3 (da) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| BRPI0921924A BRPI0921924A2 (pt) | 2008-11-20 | 2009-11-19 | composto, composição farmacêutica, uso de uma composição farmacêutica, e de um composto, e, método de tratamento de uma doença ou distúrbio mediado pelo receptor m1 muscarínico |
| PL09761104T PL2358686T3 (pl) | 2008-11-20 | 2009-11-19 | Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1 |
| EP09761104A EP2358686B1 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| CN200980155011.4A CN102292323B (zh) | 2008-11-20 | 2009-11-19 | 芳基甲基苯并喹唑啉酮 m1受体正向变构调节剂 |
| US13/129,593 US8557832B2 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators |
| ES09761104T ES2393694T3 (es) | 2008-11-20 | 2009-11-19 | Moduladores alostéricos positivos del receptor de aril metil benzoquinazolinona M1 |
| AU2009316578A AU2009316578B2 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| RS20120522A RS52528B (en) | 2008-11-20 | 2009-11-19 | ARYL METHYL BENZOHINAZOLINONE AS POSITIVE M1 RECEPTOR MODULATORS |
| SI200930460T SI2358686T1 (sl) | 2008-11-20 | 2009-11-19 | Aril metil benzokuinazolinon M1 receptor pozitivnih alosteričnih modulatorjev |
| CA2743562A CA2743562C (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| KR1020117011415A KR101305590B1 (ko) | 2008-11-20 | 2009-11-19 | 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제 |
| NZ592961A NZ592961A (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| MX2011005284A MX2011005284A (es) | 2008-11-20 | 2009-11-19 | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1. |
| EA201170705A EA019098B1 (ru) | 2008-11-20 | 2009-11-19 | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 |
| SG2011036472A SG171769A1 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| IL212573A IL212573A (en) | 2008-11-20 | 2011-04-28 | Aryl Methyl Benzokinazulinone Compounds |
| TN2011000209A TN2011000209A1 (en) | 2008-11-20 | 2011-04-29 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| ZA2011/03612A ZA201103612B (en) | 2008-11-20 | 2011-05-17 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| MA33939A MA32898B1 (fr) | 2008-11-20 | 2011-06-13 | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone |
| HK11108976.8A HK1154587A1 (en) | 2008-11-20 | 2011-08-25 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| HRP20120992AT HRP20120992T1 (hr) | 2008-11-20 | 2012-12-03 | Aril metil benzokinazolinon kao pozitivni alosterni modulatori receptora m1 |
| US14/013,184 US8883810B2 (en) | 2008-11-20 | 2013-08-29 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| US14/509,580 US20150031713A1 (en) | 2008-11-20 | 2014-10-08 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| US14/828,216 US9708273B2 (en) | 2008-11-20 | 2015-08-17 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19974008P | 2008-11-20 | 2008-11-20 | |
| US61/199,740 | 2008-11-20 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/129,593 A-371-Of-International US8557832B2 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators |
| US14/013,184 Continuation US8883810B2 (en) | 2008-11-20 | 2013-08-29 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010059773A1 true WO2010059773A1 (en) | 2010-05-27 |
Family
ID=41565956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2009/065060 WO2010059773A1 (en) | 2008-11-20 | 2009-11-19 | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US8557832B2 (pl) |
| EP (1) | EP2358686B1 (pl) |
| JP (1) | JP5102397B2 (pl) |
| KR (1) | KR101305590B1 (pl) |
| CN (1) | CN102292323B (pl) |
| BR (1) | BRPI0921924A2 (pl) |
| CA (1) | CA2743562C (pl) |
| CO (1) | CO6361928A2 (pl) |
| CR (1) | CR20110268A (pl) |
| CY (1) | CY1113665T1 (pl) |
| DK (1) | DK2358686T3 (pl) |
| DO (1) | DOP2011000135A (pl) |
| EA (1) | EA019098B1 (pl) |
| EC (1) | ECSP11011066A (pl) |
| ES (1) | ES2393694T3 (pl) |
| GE (1) | GEP20156348B (pl) |
| GT (1) | GT201100127A (pl) |
| HK (1) | HK1154587A1 (pl) |
| HN (1) | HN2011001358A (pl) |
| HR (1) | HRP20120992T1 (pl) |
| IL (1) | IL212573A (pl) |
| MA (1) | MA32898B1 (pl) |
| MX (1) | MX2011005284A (pl) |
| MY (1) | MY162502A (pl) |
| NI (1) | NI201100100A (pl) |
| NZ (1) | NZ592961A (pl) |
| PE (1) | PE20120031A1 (pl) |
| PL (1) | PL2358686T3 (pl) |
| PT (1) | PT2358686E (pl) |
| RS (1) | RS52528B (pl) |
| SG (1) | SG171769A1 (pl) |
| SI (1) | SI2358686T1 (pl) |
| SV (1) | SV2011003912A (pl) |
| TN (1) | TN2011000209A1 (pl) |
| UA (1) | UA100459C2 (pl) |
| WO (1) | WO2010059773A1 (pl) |
| ZA (1) | ZA201103612B (pl) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011025851A1 (en) * | 2009-08-31 | 2011-03-03 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| WO2011159553A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| EP2512245A1 (en) * | 2009-12-14 | 2012-10-24 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| EP2515656A1 (en) * | 2009-12-21 | 2012-10-31 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| WO2013024006A1 (en) | 2011-08-12 | 2013-02-21 | Basf Se | Anthranilamide compounds and their use as pesticides |
| WO2013024005A1 (en) | 2011-08-12 | 2013-02-21 | Basf Se | Anthranilamide compounds and their use as pesticides |
| WO2013105117A1 (en) * | 2012-01-10 | 2013-07-18 | Council Of Scientific & Industrial Research | Cu-MEDIATED ANNULATION FOR THE PRODUCTION OF 1-AMINO-2-NAPHTHALENECARBOXYLIC ACID DERIVATIVES |
| EP2624697A1 (en) * | 2010-10-04 | 2013-08-14 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2709624A1 (en) * | 2011-05-17 | 2014-03-26 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
| US9260418B2 (en) | 2009-08-31 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators |
| WO2017069173A1 (ja) * | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| US9878989B2 (en) | 2015-06-26 | 2018-01-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9926312B2 (en) | 2013-10-01 | 2018-03-27 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
| WO2018069841A1 (en) * | 2016-10-14 | 2018-04-19 | Pi Industries Ltd | 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms |
| WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
| EP3265466A4 (en) * | 2015-03-06 | 2018-12-26 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| US10214519B2 (en) | 2016-09-23 | 2019-02-26 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US10227350B2 (en) | 2016-09-23 | 2019-03-12 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US10308633B2 (en) | 2015-09-30 | 2019-06-04 | Merck Sharp & Dohme Corp. | Process for making M1 receptor positive allosteric modulators |
| US10479770B2 (en) | 2016-09-23 | 2019-11-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| WO2020067455A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
| US11021448B2 (en) | 2016-11-01 | 2021-06-01 | Hoffmann-La Roche Inc. | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases |
| EP4019018A1 (en) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2022194799A1 (de) | 2021-03-18 | 2022-09-22 | Merck Patent Gmbh | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02421B (me) | 2009-12-17 | 2016-09-20 | Merck Sharp & Dohme | Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2015159905A1 (ja) * | 2014-04-17 | 2015-10-22 | 住友化学株式会社 | ニトロ化合物の製造方法 |
| EP3356333A4 (en) * | 2015-09-30 | 2019-03-27 | Merck Sharp & Dohme Corp. | CRYSTAL FORMS OF AN M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR |
| SG11201808003RA (en) | 2016-04-15 | 2018-10-30 | Abbvie Inc | Bromodomain inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753663A (en) * | 1995-10-02 | 1998-05-19 | Syntex (U.S.A.) Inc. | Pyrimidine derivatives |
| EP1122253A1 (en) * | 1998-10-16 | 2001-08-08 | Sumitomo Pharmaceuticals Company, Limited | Quinazolinone derivatives |
| WO2008002621A2 (en) * | 2006-06-28 | 2008-01-03 | Merck & Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| JP2005089298A (ja) * | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| WO2004073639A2 (en) * | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| ES2334708T3 (es) * | 2005-05-04 | 2010-03-15 | F. Hoffmann-La Roche Ag | (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht. |
| EP2624697B1 (en) * | 2010-10-04 | 2015-11-25 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
-
2009
- 2009-11-19 CA CA2743562A patent/CA2743562C/en active Active
- 2009-11-19 MX MX2011005284A patent/MX2011005284A/es active IP Right Grant
- 2009-11-19 DK DK09761104.0T patent/DK2358686T3/da active
- 2009-11-19 SG SG2011036472A patent/SG171769A1/en unknown
- 2009-11-19 ES ES09761104T patent/ES2393694T3/es active Active
- 2009-11-19 CN CN200980155011.4A patent/CN102292323B/zh active Active
- 2009-11-19 MY MYPI2011002215A patent/MY162502A/en unknown
- 2009-11-19 JP JP2011537601A patent/JP5102397B2/ja active Active
- 2009-11-19 US US13/129,593 patent/US8557832B2/en active Active
- 2009-11-19 RS RS20120522A patent/RS52528B/en unknown
- 2009-11-19 WO PCT/US2009/065060 patent/WO2010059773A1/en active Application Filing
- 2009-11-19 EA EA201170705A patent/EA019098B1/ru not_active IP Right Cessation
- 2009-11-19 NZ NZ592961A patent/NZ592961A/xx not_active IP Right Cessation
- 2009-11-19 EP EP09761104A patent/EP2358686B1/en active Active
- 2009-11-19 UA UAA201107595A patent/UA100459C2/ru unknown
- 2009-11-19 BR BRPI0921924A patent/BRPI0921924A2/pt active Search and Examination
- 2009-11-19 GE GEAP200912265A patent/GEP20156348B/en unknown
- 2009-11-19 KR KR1020117011415A patent/KR101305590B1/ko active IP Right Grant
- 2009-11-19 PL PL09761104T patent/PL2358686T3/pl unknown
- 2009-11-19 PT PT97611040T patent/PT2358686E/pt unknown
- 2009-11-19 SI SI200930460T patent/SI2358686T1/sl unknown
- 2009-11-19 PE PE2011001058A patent/PE20120031A1/es not_active Application Discontinuation
-
2011
- 2011-04-28 IL IL212573A patent/IL212573A/en not_active IP Right Cessation
- 2011-04-29 TN TN2011000209A patent/TN2011000209A1/fr unknown
- 2011-05-12 DO DO2011000135A patent/DOP2011000135A/es unknown
- 2011-05-17 ZA ZA2011/03612A patent/ZA201103612B/en unknown
- 2011-05-17 NI NI201100100A patent/NI201100100A/es unknown
- 2011-05-17 GT GT201100127A patent/GT201100127A/es unknown
- 2011-05-19 HN HN2011001358A patent/HN2011001358A/es unknown
- 2011-05-20 SV SV2011003912A patent/SV2011003912A/es unknown
- 2011-05-20 CR CR20110268A patent/CR20110268A/es unknown
- 2011-05-20 EC EC2011011066A patent/ECSP11011066A/es unknown
- 2011-05-24 CO CO11063884A patent/CO6361928A2/es active IP Right Grant
- 2011-06-13 MA MA33939A patent/MA32898B1/fr unknown
- 2011-08-25 HK HK11108976.8A patent/HK1154587A1/xx not_active IP Right Cessation
-
2012
- 2012-12-03 HR HRP20120992AT patent/HRP20120992T1/hr unknown
- 2012-12-17 CY CY20121101227T patent/CY1113665T1/el unknown
-
2013
- 2013-08-29 US US14/013,184 patent/US8883810B2/en active Active
-
2014
- 2014-10-08 US US14/509,580 patent/US20150031713A1/en not_active Abandoned
-
2015
- 2015-08-17 US US14/828,216 patent/US9708273B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753663A (en) * | 1995-10-02 | 1998-05-19 | Syntex (U.S.A.) Inc. | Pyrimidine derivatives |
| EP1122253A1 (en) * | 1998-10-16 | 2001-08-08 | Sumitomo Pharmaceuticals Company, Limited | Quinazolinone derivatives |
| WO2008002621A2 (en) * | 2006-06-28 | 2008-01-03 | Merck & Co., Inc. | Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
Cited By (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915812A1 (en) * | 2009-08-31 | 2015-09-09 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| US9260418B2 (en) | 2009-08-31 | 2016-02-16 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators |
| US20120157438A1 (en) * | 2009-08-31 | 2012-06-21 | Merck Sharp & Dohme Corp | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| RU2507204C2 (ru) * | 2009-08-31 | 2014-02-20 | Мерк Шарп И Доум Корп. | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона |
| WO2011025851A1 (en) * | 2009-08-31 | 2011-03-03 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| US8846702B2 (en) | 2009-08-31 | 2014-09-30 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators |
| EP2512245A1 (en) * | 2009-12-14 | 2012-10-24 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| EP2512245A4 (en) * | 2009-12-14 | 2013-05-15 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF PYRIDOQUINAZOLINONE M1 RECEPTORS |
| EP2515656A4 (en) * | 2009-12-21 | 2013-05-15 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC AMINOBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS |
| EP2515656A1 (en) * | 2009-12-21 | 2012-10-31 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| WO2011159553A1 (en) * | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
| US8697690B2 (en) | 2010-07-01 | 2014-04-15 | Merck Sharp & Dohme Corp. | Isoindolone M1 receptor positive allosteric modulators |
| EP2624697A1 (en) * | 2010-10-04 | 2013-08-14 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| EP2624697A4 (en) * | 2010-10-04 | 2014-04-30 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC DIHYDROBENZOCHINAZOLINONE M1 RECEPTOR MODULATORS |
| EP2709624A4 (en) * | 2011-05-17 | 2014-11-19 | Merck Sharp & Dohme | POSITIVE N-METHYL-TETRAHYDROCHINOLINE M1 RECEPTOR MODULATORS |
| EP2709624A1 (en) * | 2011-05-17 | 2014-03-26 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| US9284312B2 (en) | 2011-05-17 | 2016-03-15 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators |
| WO2013024005A1 (en) | 2011-08-12 | 2013-02-21 | Basf Se | Anthranilamide compounds and their use as pesticides |
| WO2013024006A1 (en) | 2011-08-12 | 2013-02-21 | Basf Se | Anthranilamide compounds and their use as pesticides |
| WO2013105117A1 (en) * | 2012-01-10 | 2013-07-18 | Council Of Scientific & Industrial Research | Cu-MEDIATED ANNULATION FOR THE PRODUCTION OF 1-AMINO-2-NAPHTHALENECARBOXYLIC ACID DERIVATIVES |
| US9233911B2 (en) | 2012-01-10 | 2016-01-12 | Council Of Scientific & Industrial Research | Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| US9926312B2 (en) | 2013-10-01 | 2018-03-27 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
| US10072005B2 (en) | 2013-10-01 | 2018-09-11 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
| EP3265466A4 (en) * | 2015-03-06 | 2018-12-26 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| US9878989B2 (en) | 2015-06-26 | 2018-01-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10899752B2 (en) | 2015-06-26 | 2021-01-26 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
| US10428056B2 (en) | 2015-06-26 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10087150B2 (en) | 2015-06-26 | 2018-10-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10323027B2 (en) | 2015-06-26 | 2019-06-18 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
| EP4019018A1 (en) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| US10308633B2 (en) | 2015-09-30 | 2019-06-04 | Merck Sharp & Dohme Corp. | Process for making M1 receptor positive allosteric modulators |
| EP3366679A4 (en) * | 2015-10-20 | 2019-04-24 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| JPWO2017069173A1 (ja) * | 2015-10-20 | 2018-08-09 | 武田薬品工業株式会社 | 複素環化合物 |
| US10548899B2 (en) | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
| WO2017069173A1 (ja) * | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| US10214519B2 (en) | 2016-09-23 | 2019-02-26 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US10227350B2 (en) | 2016-09-23 | 2019-03-12 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US10479770B2 (en) | 2016-09-23 | 2019-11-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US11155517B2 (en) | 2016-10-14 | 2021-10-26 | Pi Industries Ltd. | 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms |
| CN109843056A (zh) * | 2016-10-14 | 2019-06-04 | 印度商皮埃企业有限公司 | 4-经取代之苯基胺衍生物及其通过对抗不要的植物病原性微生物而保护作物之用途 |
| TWI825003B (zh) * | 2016-10-14 | 2023-12-11 | 印度商皮埃企業有限公司 | ４－經取代之苯基胺衍生物及其藉由對抗不要的植物病原性真菌而保護作物之用途 |
| WO2018069841A1 (en) * | 2016-10-14 | 2018-04-19 | Pi Industries Ltd | 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms |
| US11021448B2 (en) | 2016-11-01 | 2021-06-01 | Hoffmann-La Roche Inc. | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases |
| WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
| KR20210068025A (ko) | 2018-09-28 | 2021-06-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
| WO2020067455A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2022194799A1 (de) | 2021-03-18 | 2022-09-22 | Merck Patent Gmbh | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9708273B2 (en) | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | |
| EP2582676B1 (en) | Tetrahydroquinoline amide m1 receptor positive allosteric modulators | |
| CA2770480C (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| EP2515656B1 (en) | Aminobenzoquinazolinone m1 receptor positive allosteric modulators | |
| US8940765B2 (en) | N-linked quinolineamide M1 receptor positive allosteric modulators | |
| CA2733588A1 (en) | N-heterocyclic m1 receptor positive allosteric modulators | |
| AU2009307892A1 (en) | Fused heterocyclic M1 receptor positive allosteric modulators | |
| US8258135B2 (en) | Quinolizidinone M1 receptor positive allosteric modulators | |
| US9284312B2 (en) | N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators | |
| AU2009241392A1 (en) | 4-oxo-1,4-dihydroquinoline M1 receptor positive allosteric modulators | |
| AU2009316578B2 (en) | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | |
| WO2017123482A1 (en) | Dihydropyrido quinazoline m1 receptor positive allosteric modulators | |
| IL212659A (en) | Explosion protection panel for nuclear, biological and chemical pollution filtering system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200980155011.4 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09761104 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 212573 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3507/DELNP/2011 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2743562 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13129593 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 20117011415 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 592961 Country of ref document: NZ Ref document number: 2011537601 Country of ref document: JP Ref document number: 001058-2011 Country of ref document: PE Ref document number: MX/A/2011/005284 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000268 Country of ref document: CR Ref document number: 2009761104 Country of ref document: EP Ref document number: 12011500987 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11063884 Country of ref document: CO |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201170705 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: A201107595 Country of ref document: UA Ref document number: 12265 Country of ref document: GE |
|
| ENP | Entry into the national phase |
Ref document number: 2009316578 Country of ref document: AU Date of ref document: 20091119 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: P-2012/0522 Country of ref document: RS |
|
| ENP | Entry into the national phase |
Ref document number: PI0921924 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110520 |